Name: Brain Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH4655
Price: 4350 USD
Availability: InStock

Brain Cancer Treatment Market Size Share Growth & Forecast 2023-2030

Brain Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Brain Cancer Treatment Market is Segmented By Therapy (Immunotherapy, Immunotherapy. Targeted Therapy, Others), By Stages(Stage I, Stage II, Stage |||, Stage IV), By Indication(Pituitary Tumor, Meningioma, Glioblastoma, Others), By Type(Primary brain cancer(benign), Secondary brain cancer(malignant)), By End-User(Hospitals, Cancer Centers, Diagnostic Centers, Ambulatory Centers, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, &nbsp;2022-2029.</h2>

<blockquote>
Brain Cancer Treatment Market&nbsp;is expected to reach at a <a href="https://www.datamintelligence.com/download-sample/brain-cancer-treatment-market">CAGR of 10%</a> during the forecast period (2022-2029).&nbsp; &nbsp;&nbsp;&nbsp;
</blockquote>

Brain Cancer Treatment Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			10%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Therapy, By Stages, By Indication, By Type, By End-User, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/brain-cancer-treatment-market">Click here</a>

Brain cancer is caused by the overgrowth of cells in the brain, which results in masses known as tumors. There are two types of brain cancer primary brain cancer and secondary brain cancer. Primary brain cancer develops in the brain tissue, whereas secondary brain cancer develops elsewhere in the body and spreads to the brain tissue. Symptoms include balance problems, seizures, sleep difficulties, unusual behavior.

<h3>Brain Cancer Treatment Market Dynamics</h3>

Brain cancer treatment market growth is driven by the increasing instances of brain cancer cases across the globe, increase in awareness of treatment option for brain cancer &nbsp;cases, favorable reimbursement polices and increase in government funding in healthcare sectors. &nbsp;

The increase in prevalance of brain cancer cases in the market will drive the market growth 

The prevalence of brain cancer such as pituitary tumor and meningioma is driving the global brain cancer treatment market market. Brain cancer is a mix of psychiatric, developmental, and neurodegenerative diseases and it is becoming a common cause of morbidity around the world.. According to the American Medical Association (AMA), more than 20% of the global population would be over 65 years old by 2050. Furthermore, by 2030, at least 60% of those aged 65 and up would have more than one chronic illness. As a result, the growing prevalence of these neurological illnesses around the world is driving the expansion of the brain cancer treatment &nbsp;market.

Furthermore, the prevalence of brain cancer is increasing at a steady rate in developed countries. This contributes to the growth of the global brain cancer treatment market market.

High cost of diagnosis is likely to hamper the market growth 

High cost of treatment is the major drawback which is likely to hamper the market. Majority of&nbsp;&nbsp; under developed and developing countries are facing this problem due to less share from the government sector. The high cost of anti-cancer drugs is a major issue for citizens in many countries. There is a lot of pressure to cut costs and show value. NextSource Biotechnology&#39;s drug treats glioblastoma and other brain tumors and can cost up to $1000 per capsule.

<h3>COVID-19 Impact Analysis</h3>

The global market for brain tumour treatments has benefited from the COVID-19 outbreak. With regard to the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&amp;D skills, and increased their manufacturing management and quality control investments.

According to 2020 Roche&#39;s quarterly reports, the company&#39;s global supply network for medicine and diagnostic tests remains intact, and pharmaceutical division sales increased by 7% over the previous year. The efficacy of oncology medications like ecentriq and Perjeta was credited with this rise. Other major players have noticed a similar trend in brain tumour medication sales. They saw an increase in global demand for oncology medications. During the global COVID-19 pandemic, market companies have responded to the rising demand for oncology medications.

<h3>Brain Cancer Treatment Market Segment Analysis</h3>

The immunotherapy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)&nbsp; &nbsp;&nbsp;&nbsp;

Immunotherapy is expected to grow at the fastest CAGR druing the forecast period. It is used to treat cancer either by activating or suppressing the immune system. Immunotherapy is mostly preferred in the treatment of glioblastoma multiforme, which is the most common primary malignant brain cancer in adults.

AstraZeneca developed AstraZeneca AZD1390 which is a highly potent brain penetrant ATM(Ataxia telangiectasia mutant) kinase inhibitor that block ATM-dependent signalling and repair of DNA double &ndash;strand breaks (DSBs) in the region.

Increasing R&amp;D initiatives to develop the immunotherapeutics to treat the brain tumors and continuous support from the government authorities to develop the chance therapeutics are projected to fuel the segment growth over the forecast period

<h3>Brain Cancer Treatment Market Geographical Analysis</h3>

North America region holds the largest market share of global brain cancer treatment market 

North America is expected to dominate the global market owing to factors such as government&rsquo;s initiative regarding growing awareness of advanced technologies . This is due to the widespread use of advanced treatment methods and the high prevalence of brain cancer.

The United States is the most promising market for brain cancer treatment due to favorable reimbursement landscape, aggressive awareness programmes, improved diagnostic measures, and the presence of major advanced therapy brands. The North American brain cancer market is forecasted to have a significant share over the forecast period. The United States market is supposed to take the lead, and this is due to the rise in the number of brain cancer patients, the developed healthcare industry, coupled with rising awareness regarding advanced technologies among the population in this region.

In the US more than 24530 adults (10690 women and 13840 men) will be diagnosed with primary cancerous tumors of the brain and spinal cord.

Meningioma is the most common type of brain cancer followed by gliomas, Eflornithin is designated as an orphan drug in the United States and received the breakthrough therapy designation for the treatment of anaplastic glioma. This is likely to positively impact the growth of the market over the forecast period.

<h3>Brain Cancer Treatment Market Competitive Landscape</h3>

The brain cancer treatment market is highly competitive with presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Novartis AG, Pfizer Inc, F.Hoffmann La Roche Ltd, Y-mAbS Therapeutics, Inc ,Merck &amp; Co.Inc, Johnson &amp; Johnson ,AstraZeneca, Bristol &ndash; Myers Squibb , Amgen Inc, GlaxoSmith Kline PLC.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the papillary thyroid carcinoma treatment market globally. For instance, in April 2021, D&amp;D PharmaJet, Inc. (D&amp;D), a clinical-stage biotechnology company, has entered into a sponsored research agreement with Yale University to optimize two novel approaches for the treatment of brain cancer and other disorders that allow immune system cells and drug molecules to bypass the blood-brain barrier (BBB). The BBB is a network of blood vessels and tissue made up of closely spaced cells that prevents harmful substances and many therapeutics from entering the brain.

Novartis AG 

Overview: Novartis India Ltd. is an Indian based pharmaceutical company. The company is engaged in the trading of drugs and pharmaceuticals. It derives revenue from operations in India. The company focuses on three divisions namely&nbsp;Pharmaceuticals, eyecare and generic medicines.

Product Portfolio:

Capmatinib: &nbsp;Capmatinib is a drug that is used to treat brain cancer that has spread throughout the body. Capmatinib belongs to the kinase inhibitor class of drugs. It works by preventing cancer cells from multiplying by stopping the action of an aberrant protein. This slows or stops cancer cells from spreading.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Brain Cancer Treatment Market?

Brain Cancer Treatment Market is expected to grow at a&nbsp;CAGR of 10%&nbsp;during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America&nbsp;region Controls&nbsp;the&nbsp;Brain Cancer Treatment Market&nbsp;during 2022-2029

Which is the fastest growing region in the Brain Cancer Treatment Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/pet-food-market">Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/organic-pet-food-market">Organic Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/freeze-dried-pet-food-market">Freeze-Dried Pet Food Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>Market Snippet by &nbsp;Therapy</li>
		<li>Market snippet by Stages</li>
		<li>Market Snippet by Indication</li>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by End User</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Growing Prevalence of brain cancer disease</li>
				<li>The introduction of new products in the market</li>
				<li>Increasing awareness of treatment option for brain cancer treatment</li>
				<li>Favorable reimbursement Policies</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Introduction of generic medicines</li>
				<li>High cost of treatment of brain cancer</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	By Therapy

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Segment</li>
			<li>Market Attractiveness Index, By Therapy Segment</li>
		</ol>
		</li>
		<li>Immunotherapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Immunotherapy</li>
		<li>Targeted Therapy</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	By Stages

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>Market Attractiveness Index, By Stages</li>
		</ol>
		</li>
		<li>Stage I*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Stage II</li>
		<li>Stage III</li>
		<li>Stage IV</li>
	</ol>
	</li>
	<li>
	By Indication

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Attractiveness Index, By Indication Segment</li>
		</ol>
		</li>
		<li>Pituitary Tumor*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Meningioma</li>
		<li>Glioblastoma</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	By Type

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Primary brain cancer(benign)*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Secondary brain cancer(malignant)</li>
	</ol>
	</li>
	<li>
	By End User

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Segment</li>
			<li>Market Attractiveness Index, By Therapy Segment</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Cancer Centers</li>
		<li>Diagnostic Centers</li>
		<li>Ambulatory Centers</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	By Region

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis(%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
			<li>U.S.</li>
			<li>Canada</li>
			<li>Mexico</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis ,and Y-o-Y&nbsp; Growth Analysis (%),By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type&nbsp;</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication</li>
			<li>&nbsp;Market Size Analysis ,and Y-o-Y Growth Analysis (%), By Type</li>
			<li>&nbsp;</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis&nbsp; (%), By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stages</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%),By Indication</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%),By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	By Competitive Landscape

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>
	By Company Profiles

	<ol>
		<li>Novartis AG*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>F. Hoffmann-La Roche Ltd</li>
		<li>Pfizer,Inc</li>
		<li>Y-mAbs Therapeutics,Inc</li>
		<li>Merck &amp; Co.Inc</li>
		<li>Johnson &amp; Johnson</li>
		<li>AstraZeneca</li>
		<li>Bristol-Myers Squibb</li>
		<li>Amgen Inc</li>
		<li>GlaxoSmith Kline PLC(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	DataM Intelligence

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

&nbsp;List of Tables

Table 1Global Brain Cancer Treatment Market Value, By Therapy, 2021, 2025 &amp; 2029($ Million)

Table 2Global Brain Cancer Treatment Market Value, By Stages, 2021, 2025 &amp; 2029($ Million)

Table 3Global Brain Cancer Treatment Market Value, By Indication, 2021, 2025 &amp; 2029($ Million)

Table 4Global Brain Cancer Treatment Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 5Global Brain Cancer Treatment Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 6Global Brain Cancer Treatment Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 7Global Brain Cancer Treatment Market Value, By Therapy, 2021, 2025 &amp; 2029($ Million)

Table 8Global Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 9Global Brain Cancer Treatment Market Value, By Stages, 2021, 2025 &amp; 2029($ Million)

Table 10Global Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 11Global Brain Cancer Treatment Market Value, By Indication, 2021, 2025 &amp; 2029($ Million)

Table 12Global Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 13Global Brain Cancer Treatment Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 14Global Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 15Global Brain Cancer Treatment Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 16Global Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 17Global Brain Cancer Treatment Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 18Global Brain Cancer Treatment Market Value, By Region, 2020-2029($ Million)

Table 19North America Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 20North America Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 21North America Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 22North America Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 23North America Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 24North America Brain Cancer Treatment Market Value, By Country, 2020-2029($ Million)

Table 25South America Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 26South America Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 27South America Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 28South America Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 29South America Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 30South America Brain Cancer Treatment Market Value, By Country, 2020-2029($ Million)

Table 31Europe Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 32Europe Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 33Europe Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 34Europe Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 35Europe Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 36Europe Brain Cancer Treatment Market Value, By Country, 2020-2029($ Million)

Table 37Asia-Pacific Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 38Asia-Pacific Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 39Asia-Pacific Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 40Asia-Pacific Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 41Asia-Pacific Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 42Asia-Pacific Brain Cancer Treatment Market Value, By Country, 2020-2029($ Million)

Table 43Middle East &amp; Africa Brain Cancer Treatment Market Value, By Therapy, 2020-2029($ Million)

Table 44Middle East &amp; Africa Brain Cancer Treatment Market Value, By Stages, 2020-2029($ Million)

Table 45Middle East &amp; Africa Brain Cancer Treatment Market Value, By Indication, 2020-2029($ Million)

Table 46Middle East &amp; Africa Brain Cancer Treatment Market Value, By Type, 2020-2029($ Million)

Table 47Middle East &amp; Africa Brain Cancer Treatment Market Value, By End User, 2020-2029($ Million)

Table 48Novartis AG: Overview

Table 49Novartis AG: Product Portfolio

Table 50Novartis AG: Key Developments

Table 51Pfizer, Inc: Overview

Table 52Pfizer, Inc: Product Portfolio

Table 53Pfizer, Inc: Key Developments

Table 54Y-mAbs Therapeutics,Inc: Overview

Table 55Y-mAbs Therapeutics,Inc: Product Portfolio

Table 56Y-mAbs Therapeutics,Inc: Key Developments

Table 57Merck &amp; Co.Inc: Overview

Table 58Merck &amp; Co.Inc: Product Portfolio

Table 59Merck &amp; Co.Inc: Key Developments

Table 60Johnson &amp; Johnson: Overview

Table 61Johnson &amp; Johnson: Product Portfolio

Table 62Johnson &amp; Johnson: Key Developments

Table 63AstraZeneca: Overview

Table 64AstraZeneca: Product Portfolio

Table 65AstraZeneca: Key Developments

Table 66Bristol-Myers Squibb: Overview

Table 67Bristol-Myers Squibb: Product Portfolio

Table 68Bristol-Myers Squibb: Key Developments

Table 69Amgen Inc: Overview

Table 70Amgen Inc: Product Portfolio

Table 71Amgen Inc: Key Developments

Table 72GlaxoSmith Kline PLC: Overview

Table 73GlaxoSmith Kline PLC: Product Portfolio

Table 74GlaxoSmith Kline PLC: Key Developments

&nbsp;List of Figures

Figure 1Global Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 2Global Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 3Global Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 4Global Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 5Global Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 6Global Brain Cancer Treatment Market Share, By Region, 2021 &amp; 2029(%)

Figure 7Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 8Global Brain Cancer Treatment Market Y-o-Y Growth, By Therapy, 2021-2029(%)

Figure 9Immunotherapy: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 10Chemotherapy: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 11Targeted Therapy: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 12Others: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 13Global Brain Cancer Treatment Market Y-o-Y Growth, By Stages, 2021-2029(%)

Figure 14Stage I: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 15Stage II: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 16Stage III: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 17Stage IV: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 18Global Brain Cancer Treatment Market Y-o-Y Growth, By Indication, 2021-2029(%)

Figure 19Pituitary Tumor: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 20Meningioma: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 21Glioblastoma: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 22Others: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 23Global Brain Cancer Treatment Market Y-o-Y Growth, By Type, 2021-2029(%)

Figure 24Primary brain cancer(benign): Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 25Secondary brain cancer(malignant): Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 26Global Brain Cancer Treatment Market Y-o-Y Growth, By End User, 2021-2029(%)

Figure 27Hospitals: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 28Cancer Centers: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 29Diagnostic Centers: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 30Ambulatory Centers: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 31Others: Global Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 32Global Brain Cancer Treatment Market Y-o-Y Growth, By Region, 2021-2029(%)

Figure 33North America Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 34North America Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 35North America Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 36North America Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 37North America Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 38North America Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 39North America Brain Cancer Treatment Market Share, By Country, 2021 &amp; 2029(%)

Figure 40South America Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 41South America Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 42South America Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 43South America Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 44South America Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 45South America Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 46South America Brain Cancer Treatment Market Share, By Country, 2021 &amp; 2029(%)

Figure 47Europe Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 48Europe Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 49Europe Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 50Europe Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 51Europe Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 52Europe Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 53Europe Brain Cancer Treatment Market Share, By Country, 2021 &amp; 2029(%)

Figure 54Asia-Pacific Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 55Asia-Pacific Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 56Asia-Pacific Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 57Asia-Pacific Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 58Asia-Pacific Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 59Asia-Pacific Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 60Asia-Pacific Brain Cancer Treatment Market Share, By Country, 2021 &amp; 2029(%)

Figure 61Middle East &amp; Africa Brain Cancer Treatment Market Value, 2020-2029($ Million)

Figure 62Middle East &amp; Africa Brain Cancer Treatment Market Share, By Therapy, 2021 &amp; 2029(%)

Figure 63Middle East &amp; Africa Brain Cancer Treatment Market Share, By Stages, 2021 &amp; 2029(%)

Figure 64Middle East &amp; Africa Brain Cancer Treatment Market Share, By Indication, 2021 &amp; 2029(%)

Figure 65Middle East &amp; Africa Brain Cancer Treatment Market Share, By Type, 2021 &amp; 2029(%)

Figure 66Middle East &amp; Africa Brain Cancer Treatment Market Share, By End User, 2021 &amp; 2029(%)

Figure 67Novartis AG: Financials

Figure 68Pfizer, Inc: Financials

Figure 69Y-mAbs Therapeutics,Inc: Financials

Figure 70Merck &amp; Co.Inc: Financials

Figure 71Johnson &amp; Johnson: Financials

Figure 72AstraZeneca: Financials

Figure 73Bristol-Myers Squibb: Financials

Figure 74Amgen Inc: Financials

Figure 75GlaxoSmith Kline PLC: Financials